What has the HARMONY Alliance achieved so far?

What has HARMONY achieved so far?

Several key milestones have been reached since the HARMONY Alliance was established:

Alignment with the latest European regulations on data privacy

Implementation of compliance with ethical rules and legislative frameworks across all countries and stakeholders in Europe

Establishment of a standard operating procedures for the submission of research questions

Creation and application of data sharing agreements

Streamlining of processes for data flow within Europe to enable the use of the HARMONY BigData platform without jeopardizing data privacy and compliance with legal and ethical requirements

Launch of the HARMONY BigData Platform

Continual population of the HARMONY BigData Platform

Submission and approval of several BigData-driven studies for the different blood cancers

Transfer of the first data sets into the HARMONY BigData Platform

With these achievements, researchers are now in the starting blocks for intense analysis of the data in the HARMONY BigData platform.

The HARMONY Alliance is a public-private European Network of Excellence, established in January 2017. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more efficient treatment strategies. We currently have 53 Partners and 32 Associated Members from 22 countries, including 9 pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Receive the latest news. Click here to subscribe!

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).